Passive transfer of MOG-specific antibodies partially restored EAE susceptibility in B–MHC II−/− mice
| Ag | Incidence | Onset | Mean maximal clinical score | Mean clinical score day 12 | Mean clinical score day 18 | Mean clinical score day 24 | Cumulative score |
| B–MHC II+/+ | |||||||
| rhMOG | 6/6 | 15.0 (±1.2) | 2.5 (±0.4) | 1.3 (±0.5) | 2.6 (±0.3) | 2.9 (±0.2) | 150.0 |
| B–MHC II−/− | |||||||
| rhMOG | 0/4 | - | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 |
| +anti-MOG mAb | 4/4 | 3.0 (±0.0) p.i. | 1.0 (±0.1) | 0.0 (±0.0) | 0.9 (±0.1) | 0.9 (±0.1) | 32.0 |
| +anti-OVA mAb | 0/4 | - | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 |
| Ag | Incidence | Onset | Mean maximal clinical score | Mean clinical score day 12 | Mean clinical score day 18 | Mean clinical score day 24 | Cumulative score |
| B–MHC II+/+ | |||||||
| rhMOG | 6/6 | 15.0 (±1.2) | 2.5 (±0.4) | 1.3 (±0.5) | 2.6 (±0.3) | 2.9 (±0.2) | 150.0 |
| B–MHC II−/− | |||||||
| rhMOG | 0/4 | - | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 |
| +anti-MOG mAb | 4/4 | 3.0 (±0.0) p.i. | 1.0 (±0.1) | 0.0 (±0.0) | 0.9 (±0.1) | 0.9 (±0.1) | 32.0 |
| +anti-OVA mAb | 0/4 | - | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 (±0.0) | 0.0 |
p.i., post injection. Onset indicates mean day of disease onset (paralytic EAE) ± SEM. Clinical score shows mean maximal score of paralytic EAE of diseased mice ± SEM. Mean clinical score shows mean score of paralytic EAE of disease mice ± SEM. Cumulative score shows sum of the daily scores of all animals from day 0 until the end of the experiment.